Physician profile
David Woodruff
NPI 1154317188
$10,372.66
in general payments reported to CMS, 2019-2025
52 companies · $1,545 in 2025
The $1,545 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,329 · 2020: $828 · 2021: $1,828 · 2022: $1,846 · 2023: $1,775 · 2024: $1,222 · 2025: $1,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,541.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,711.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,704.09 | 2021-2025 | Vraylar, Linzess, Qulipta |
| Astrazeneca Pharmaceuticals LP | $828.25 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $640.83 | 2019-2025 | |
| Lilly USA, LLC | $562.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $505.08 | 2019-2024 | Prolia, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $478.24 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $462.87 | 2019-2023 | Verquvo, Belsomra, Steglujan |
| Axsome Therapeutics, INC. | $239.83 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Novartis Pharmaceuticals Corporation | $231.78 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $184.41 | 2022-2025 | Rexulti |
| Abbott Laboratories | $179.38 | 2022-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.56 | 2022-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $161.86 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $159.36 | 2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Woodruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.